$IBRX
ImmunityBio, Inc.

2020 Q4 Form 10-K Financial Statement

#000156459021010945 Filed on March 04, 2021

View on sec.gov

Income Statement

Concept 2020 Q4 2020 Q1 2020
Revenue $21.00K $165.0K $605.0K
YoY Change 133.33% 3200.0% -72.52%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $10.65M $9.493M $71.32M
YoY Change 158.5% 57.17% 53.52%
% of Gross Profit
Research & Development $17.06M $27.37M $139.5M
YoY Change 42.17% 133.97% 24.56%
% of Gross Profit
Depreciation & Amortization $2.290M $3.500M $12.70M
YoY Change 3.62% 46.14% -9.29%
% of Gross Profit
Operating Expenses $30.91M $18.61M $221.5M
YoY Change 91.73% 1.46% 39.78%
Operating Profit -$30.89M -$36.70M -$220.9M
YoY Change 91.71% 100.17% 41.36%
Interest Expense $410.0K $1.889M $9.074M
YoY Change 32.26% 360.73% 53.28%
% of Operating Profit
Other Income/Expense, Net -$1.660M -$707.0K -$5.153M
YoY Change -1760.0% -1604.26% 28.44%
Pretax Income -$32.13M -$37.41M -$226.0M
YoY Change 104.65% 108.75% 41.04%
Income Tax $0.00 $18.00K -$1.846M
% Of Pretax Income
Net Earnings -$32.13M -$18.38M -$221.9M
YoY Change 105.43% 2.78% 40.61%
Net Earnings / Revenue -153009.52% -11141.21% -36669.59%
Basic Earnings Per Share -$0.59
Diluted Earnings Per Share -$295.7K -$99.57K -$0.59
COMMON SHARES
Basic Shares Outstanding 377.1M shares
Diluted Shares Outstanding 377.1M shares

Balance Sheet

Concept 2020 Q4 2020 Q1 2020
SHORT-TERM ASSETS
Cash & Short-Term Investments $96.10M $40.20M $96.10M
YoY Change -14.15% -59.21% 85.88%
Cash & Equivalents $34.92M $58.65M $34.90M
Short-Term Investments $61.10M $23.30M $61.10M
Other Short-Term Assets $110.0K $78.00K $10.60M
YoY Change 358.33% -2.5% 178.95%
Inventory
Prepaid Expenses
Receivables $0.00 $0.00
Other Receivables $5.000M $5.000M
Total Short-Term Assets $111.7M $44.10M $111.7M
YoY Change 100.36% -61.12% 100.18%
LONG-TERM ASSETS
Property, Plant & Equipment $72.54M $69.60M $90.70M
YoY Change 19.9% 2.47% 25.62%
Goodwill
YoY Change
Intangibles $1.463M
YoY Change
Long-Term Investments $8.800M $9.300M $8.800M
YoY Change -18.52% -30.6% -18.52%
Other Assets $2.598M $4.100M $1.700M
YoY Change -40.77% 1205.73% -61.36%
Total Long-Term Assets $109.7M $82.90M $109.7M
YoY Change 25.53% -12.58% 25.66%
TOTAL ASSETS
Total Short-Term Assets $111.7M $44.10M $111.7M
Total Long-Term Assets $109.7M $82.90M $109.7M
Total Assets $221.4M $127.0M $221.4M
YoY Change 54.68% -39.02% 54.72%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $11.51M $3.100M $11.50M
YoY Change 558.09% 10.56% 576.47%
Accrued Expenses $36.77M $9.800M $38.80M
YoY Change 588.21% -51.59% 356.47%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $16.30M $16.30M
YoY Change 1937.5% 1937.5%
Total Short-Term Liabilities $68.13M $14.25M $68.10M
YoY Change 489.45% -48.57% 487.07%
LONG-TERM LIABILITIES
Long-Term Debt $254.4M $0.00 $254.4M
YoY Change
Other Long-Term Liabilities $1.035M $10.20M $17.20M
YoY Change -90.5% -20.31% 57.8%
Total Long-Term Liabilities $1.035M $10.20M $271.6M
YoY Change -90.5% -20.31% 2391.74%
TOTAL LIABILITIES
Total Short-Term Liabilities $68.13M $14.25M $68.10M
Total Long-Term Liabilities $1.035M $10.20M $271.6M
Total Liabilities $339.9M $24.43M $341.2M
YoY Change 1414.31% -39.68% 1423.21%
SHAREHOLDERS EQUITY
Retained Earnings -$1.615B -$680.6M
YoY Change 143.91%
Common Stock $1.495B $783.3M
YoY Change 90.96%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares $163.8K
Shareholders Equity -$119.8M $102.6M -$119.8M
YoY Change
Total Liabilities & Shareholders Equity $221.4M $127.0M $221.4M
YoY Change 54.68% -39.02% 54.72%

Cashflow Statement

Concept 2020 Q4 2020 Q1 2020
OPERATING ACTIVITIES
Net Income -$32.13M -$18.38M -$221.9M
YoY Change 105.43% 2.78% 40.61%
Depreciation, Depletion And Amortization $2.290M $3.500M $12.70M
YoY Change 3.62% 46.14% -9.29%
Cash From Operating Activities -$23.05M -$31.11M -$171.7M
YoY Change 54.91% 137.86% 12.9%
INVESTING ACTIVITIES
Capital Expenditures -$400.0K $315.0K $1.669M
YoY Change -41.18% -85.03% -61.07%
Acquisitions
YoY Change
Other Investing Activities $6.970M $14.31M -$17.95M
YoY Change -45.72% -182.43% -170.01%
Cash From Investing Activities $6.570M $13.99M -$19.81M
YoY Change -46.01% -171.92% -206.79%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net -$86.30M
YoY Change 213.84%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 250.0K -123.0K $150.7M
YoY Change -516.67% -100.31% 31.85%
NET CHANGE
Cash From Operating Activities -23.05M -31.11M -$171.7M
Cash From Investing Activities 6.570M 13.99M -$19.81M
Cash From Financing Activities 250.0K -123.0K $150.7M
Net Change In Cash -16.23M -17.15M -$40.89M
YoY Change 485.92% -357.54% 111.86%
FREE CASH FLOW
Cash From Operating Activities -$23.05M -$31.11M -$171.7M
Capital Expenditures -$400.0K $315.0K $1.669M
Free Cash Flow -$22.65M -$31.42M -$173.4M
YoY Change 59.51% 106.97% 10.87%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020 dei Entity Shell Company
EntityShellCompany
false
CY2020 us-gaap Lease Practical Expedients Package
LeasePracticalExpedientsPackage
true
CY2020 nk Cash And Cash Equivalents Original Maturities
CashAndCashEquivalentsOriginalMaturities
P3M
CY2020 nk Period Of Cumulative Ownership Change
PeriodOfCumulativeOwnershipChange
P3Y
CY2020 nk Net Operating Loss Carrybacks Period
NetOperatingLossCarrybacksPeriod
P5Y
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0
CY2020 nk Available For Sale Securities Debt Securities Period
AvailableForSaleSecuritiesDebtSecuritiesPeriod
P3M18D
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
24651000
CY2019Q4 us-gaap Assets
Assets
143123000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1749000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5343000
CY2019Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
486000
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1438000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
9814000
CY2020Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
5269000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5500000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3206000
CY2020Q4 us-gaap Liabilities
Liabilities
34465000
CY2019Q4 us-gaap Liabilities
Liabilities
22444000
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
11000
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
10000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
872078000
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
782965000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-122000
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-105000
CY2020 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1121000
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4386000
CY2020Q4 us-gaap Assets
Assets
151858000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4101000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8343000
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
108726551
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
108726551
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
98460404
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
98460404
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-91626000
CY2020 us-gaap Investment Income Net
InvestmentIncomeNet
366000
CY2019 us-gaap Investment Income Net
InvestmentIncomeNet
1642000
CY2019 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
19000
CY2018 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
433000
CY2018 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
236000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-754574000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-662191000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
117393000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
120679000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
151858000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
143123000
CY2019 us-gaap Revenues
Revenues
43000
CY2018 us-gaap Revenues
Revenues
47000
CY2018 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
55718000
CY2020 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
0
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
218844000
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
23382000
CY2018 us-gaap Stock And Warrants Issued During Period Value Preferred Stock And Warrants
StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
57000
CY2018 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
0
CY2018 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
123000
CY2018 us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
228000
CY2018 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
114000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-96226000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
146006000
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2627000
CY2019 us-gaap Stock And Warrants Issued During Period Value Preferred Stock And Warrants
StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
35151000
CY2019 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4070000
CY2019 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
0
CY2019 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
127000
CY2019 us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
501000
CY2019 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
162000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-65789000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
120679000
CY2020 nk Stock Offering Costs
StockOfferingCosts
4373000
CY2020 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
86302000
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1176000
CY2020 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
503000
CY2020 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-17000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-92383000
CY2020 us-gaap Profit Loss
ProfitLoss
-92383000
CY2019 us-gaap Profit Loss
ProfitLoss
-65789000
CY2018 us-gaap Profit Loss
ProfitLoss
-96226000
CY2020 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
9147000
CY2019 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
9012000
CY2018 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
9555000
CY2020 nk Operating Lease Right Of Use Asset Non Cash Lease Expense
OperatingLeaseRightOfUseAssetNonCashLeaseExpense
3430000
CY2019 nk Operating Lease Right Of Use Asset Non Cash Lease Expense
OperatingLeaseRightOfUseAssetNonCashLeaseExpense
2604000
CY2018 nk Operating Lease Right Of Use Asset Non Cash Lease Expense
OperatingLeaseRightOfUseAssetNonCashLeaseExpense
0
CY2020 us-gaap Equity Securities Without Readily Determinable Fair Value Downward Price Adjustment Annual Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount
1405000
CY2019 us-gaap Equity Securities Without Readily Determinable Fair Value Downward Price Adjustment Annual Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount
0
CY2018 us-gaap Equity Securities Without Readily Determinable Fair Value Downward Price Adjustment Annual Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount
0
CY2020 us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
-8000
CY2019 us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
-4000
CY2018 us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
3000
CY2020 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-4000
CY2019 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
0
CY2018 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-209000
CY2020 nk Non Cash Interest Income Expense From Operating Activities
NonCashInterestIncomeExpenseFromOperatingActivities
251000
CY2019 nk Non Cash Interest Income Expense From Operating Activities
NonCashInterestIncomeExpenseFromOperatingActivities
-246000
CY2018 nk Non Cash Interest Income Expense From Operating Activities
NonCashInterestIncomeExpenseFromOperatingActivities
-291000
CY2020 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2019 us-gaap Asset Impairment Charges
AssetImpairmentCharges
869000
CY2018 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2020 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2019 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2018 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-498000
CY2020 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
339000
CY2019 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
4063000
CY2018 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
1151000
CY2020 nk Increase Decrease In Accounts Payable Current
IncreaseDecreaseInAccountsPayableCurrent
2142000
CY2019 nk Increase Decrease In Accounts Payable Current
IncreaseDecreaseInAccountsPayableCurrent
41000
CY2018 nk Increase Decrease In Accounts Payable Current
IncreaseDecreaseInAccountsPayableCurrent
-1100000
CY2020 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
3686000
CY2019 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-12020000
CY2018 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
12708000
CY2020 us-gaap Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
5034000
CY2019 us-gaap Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
-1093000
CY2018 us-gaap Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
-685000
CY2020 nk Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-3941000
CY2019 nk Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-3076000
CY2018 nk Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
0
CY2020 nk Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
0
CY2019 nk Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
0
CY2018 nk Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
-508000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-70453000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-61362000
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-63381000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2639000
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4182000
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
13102000
CY2020 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0
CY2019 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0
CY2018 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
412000
CY2020 us-gaap Payments To Acquire Held To Maturity Securities
PaymentsToAcquireHeldToMaturitySecurities
0
CY2019 us-gaap Payments To Acquire Held To Maturity Securities
PaymentsToAcquireHeldToMaturitySecurities
0
CY2018 us-gaap Payments To Acquire Held To Maturity Securities
PaymentsToAcquireHeldToMaturitySecurities
723000
CY2020 nk Payments To Acquire Investments In Equity Securities
PaymentsToAcquireInvestmentsInEquitySecurities
0
CY2019 nk Payments To Acquire Investments In Equity Securities
PaymentsToAcquireInvestmentsInEquitySecurities
3000
CY2018 nk Payments To Acquire Investments In Equity Securities
PaymentsToAcquireInvestmentsInEquitySecurities
0
CY2020 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
91572000
CY2019 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
86618000
CY2018 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
94770000
CY2020 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
65350000
CY2019 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
109730000
CY2018 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
165284000
CY2020 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
8272000
CY2019 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
2529000
CY2018 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
0
CY2020 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
86302000
CY2019 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
CY2018 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
CY2018 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
CY2020 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1176000
CY2019 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
4070000
CY2019 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
35151000
CY2018 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
57000
CY2020 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
0
CY2019 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
0
CY2018 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
477000
CY2020 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
0
CY2019 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
501000
CY2018 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
228000
CY2020 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
503000
CY2019 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
127000
CY2018 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
123000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
86975000
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
38593000
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-771000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-4067000
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-1313000
CY2018 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-7051000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
15687000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
17000000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
24051000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
11620000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
15687000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
17000000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11441000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15508000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16821000
CY2020Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
179000
CY2019Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
179000
CY2018Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
179000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
11620000
CY2020 us-gaap Interest Paid Net
InterestPaidNet
40000
CY2019 us-gaap Interest Paid Net
InterestPaidNet
19000
CY2018 us-gaap Interest Paid Net
InterestPaidNet
475000
CY2020 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
8000
CY2019 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
3000
CY2018 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
4000
CY2020 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
5164000
CY2019 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
800000
CY2018 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
CY2020 us-gaap Stock Issued1
StockIssued1
1233000
CY2019 us-gaap Stock Issued1
StockIssued1
29000
CY2018 us-gaap Stock Issued1
StockIssued1
94000
CY2018 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
4664000
CY2020 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
0
CY2019 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
751000
CY2018 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
0
CY2020 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-17000
CY2019 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
258000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-754600000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-70500000
CY2020 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, we evaluate our estimates, including those related to valuation of equity-based awards, deferred income taxes and related valuation allowances, preclinical and clinical trial accruals, impairment assessments, the measurement of right-of-use assets and lease liabilities, useful lives of long-lived assets, loss contingencies, fair value measurements, and the assessment of the company’s ability to fund its operations for at least the next twelve months from the date of issuance of these financial statements. We base our estimates on historical experience and on various other market-specific and relevant assumptions that we believe to be reasonable under the circumstances. Estimates are assessed each period and updated to reflect current information, such as the economic considerations related to the impact that the ongoing coronavirus pandemic could have on our significant accounting estimates. Actual results could differ from those estimates.</p>
CY2020 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of Credit Risk and Other Risks and Uncertainties</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject us to concentrations of risk consist principally of cash and cash equivalents and marketable debt securities.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our cash and cash equivalents are held by one major financial institution in the U.S. and one in Korea. We minimize credit risk associated with our cash and cash equivalents by periodically evaluating the credit quality of our primary financial institutions. While we maintain cash deposits in FDIC insured financial institutions in excess of federally insured limits, we do not believe that we are exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. We have not experienced any losses on such accounts.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product candidates developed by us will require approvals or clearances from the U.S. Food and Drug Administration, or FDA, or international regulatory agencies prior to commercial sales. There can be no assurance that any of our product candidates will receive any of the required approvals or clearances. If we were to be denied approval or clearance or any such approval or clearance was to be delayed, it would have a material adverse impact on us.</p>
CY2020 nk Maximum Original Maturity Period Of Short Term Marketable Securities
MaximumOriginalMaturityPeriodOfShortTermMarketableSecurities
P12M
CY2020 nk Minimum Original Maturity Period Of Long Term Marketable Securities
MinimumOriginalMaturityPeriodOfLongTermMarketableSecurities
P12M
CY2020 us-gaap Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net
OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet
0
CY2019 us-gaap Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net
OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet
0
CY2018 us-gaap Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net
OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet
0
CY2020 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P4Y
CY2020Q4 nk Fair Value Inputs Transfers Into Or Out Of Level One Level Two Or Level Three Categories
FairValueInputsTransfersIntoOrOutOfLevelOneLevelTwoOrLevelThreeCategories
0
CY2019Q4 nk Fair Value Inputs Transfers Into Or Out Of Level One Level Two Or Level Three Categories
FairValueInputsTransfersIntoOrOutOfLevelOneLevelTwoOrLevelThreeCategories
0
CY2018Q4 nk Fair Value Inputs Transfers Into Or Out Of Level One Level Two Or Level Three Categories
FairValueInputsTransfersIntoOrOutOfLevelOneLevelTwoOrLevelThreeCategories
0
CY2020 us-gaap Lessee Operating Lease Description
LesseeOperatingLeaseDescription
elected not to recognize right-of-use assets and lease liabilities for qualifying short-term leases with an initial lease term of 12 months or less at lease inception
CY2020Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2019Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2015Q4 us-gaap Stock Repurchase Program Authorized Amount1
StockRepurchaseProgramAuthorizedAmount1
50000000.0
CY2020 nk Variable Consideration Related To Milestone Payment
VariableConsiderationRelatedToMilestonePayment
0
CY2020 us-gaap Revenue Recognition Milestone Method Revenue Recognized
RevenueRecognitionMilestoneMethodRevenueRecognized
0
CY2020Q4 nk Number Of Products Approved For Commercial Sale
NumberOfProductsApprovedForCommercialSale
0
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3984852
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5646378
CY2018 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
24950411
CY2020Q4 us-gaap Prepaid Rent
PrepaidRent
589000
CY2019Q4 us-gaap Prepaid Rent
PrepaidRent
392000
CY2020Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
473000
CY2019Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
222000
CY2020Q4 nk Prepaid Supplies With Related Party
PrepaidSuppliesWithRelatedParty
281000
CY2020Q4 nk Prepaid Preclinical And Clinical Trial Services With Related Party
PrepaidPreclinicalAndClinicalTrialServicesWithRelatedParty
4626000
CY2019Q4 nk Prepaid Preclinical And Clinical Trial Services With Related Party
PrepaidPreclinicalAndClinicalTrialServicesWithRelatedParty
1021000
CY2020Q4 nk Insurance Premium Financing Asset
InsurancePremiumFinancingAsset
1421000
CY2019Q4 nk Insurance Premium Financing Asset
InsurancePremiumFinancingAsset
757000
CY2020Q4 us-gaap Prepaid Insurance
PrepaidInsurance
657000
CY2019Q4 us-gaap Prepaid Insurance
PrepaidInsurance
372000
CY2020Q4 nk Prepaid Services
PrepaidServices
607000
CY2019Q4 nk Prepaid Services
PrepaidServices
440000
CY2019Q4 nk Prepaid Supplies With Related Party
PrepaidSuppliesWithRelatedParty
467000
CY2020Q4 nk Prepaid Equipment Maintenance
PrepaidEquipmentMaintenance
243000
CY2019Q4 nk Prepaid Equipment Maintenance
PrepaidEquipmentMaintenance
251000
CY2020Q4 nk Prepaid License Fees
PrepaidLicenseFees
233000
CY2019Q4 nk Prepaid License Fees
PrepaidLicenseFees
78000
CY2020Q4 nk Laboratory Equipment Deposit
LaboratoryEquipmentDeposit
66000
CY2019Q4 nk Laboratory Equipment Deposit
LaboratoryEquipmentDeposit
0
CY2020Q4 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
45000
CY2019Q4 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
47000
CY2020Q4 us-gaap Insurance Settlements Receivable Current
InsuranceSettlementsReceivableCurrent
0
CY2019Q4 us-gaap Insurance Settlements Receivable Current
InsuranceSettlementsReceivableCurrent
34000
CY2020Q4 us-gaap Other Assets Current
OtherAssetsCurrent
44000
CY2019Q4 us-gaap Other Assets Current
OtherAssetsCurrent
24000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
9285000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4105000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
81044000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
79108000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
27117000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
18607000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
53927000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
60501000
CY2020 us-gaap Depreciation
Depreciation
9100000
CY2019 us-gaap Depreciation
Depreciation
8400000
CY2018 us-gaap Depreciation
Depreciation
7300000
CY2019 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
600000
CY2020Q4 nk Prepaid Software License Fees In Other Assets
PrepaidSoftwareLicenseFeesInOtherAssets
318000
CY2019Q4 nk Prepaid Software License Fees In Other Assets
PrepaidSoftwareLicenseFeesInOtherAssets
0
CY2020Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
179000
CY2019Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
179000
CY2020Q4 nk Prepaid Preclinical And Clinical Trial Services With Related Party In Other Assets
PrepaidPreclinicalAndClinicalTrialServicesWithRelatedPartyInOtherAssets
92000
CY2019Q4 nk Prepaid Preclinical And Clinical Trial Services With Related Party In Other Assets
PrepaidPreclinicalAndClinicalTrialServicesWithRelatedPartyInOtherAssets
4075000
CY2020Q4 us-gaap Security Deposit
SecurityDeposit
481000
CY2019Q4 us-gaap Security Deposit
SecurityDeposit
113000
CY2020Q4 us-gaap Due From Related Parties Noncurrent
DueFromRelatedPartiesNoncurrent
51000
CY2019Q4 us-gaap Due From Related Parties Noncurrent
DueFromRelatedPartiesNoncurrent
19000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1121000
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4386000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2920000
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
975000
CY2020Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
2236000
CY2019Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
2002000
CY2020Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
1368000
CY2019Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
1064000
CY2020Q4 nk Accrued Laboratory Equipment And Supplies
AccruedLaboratoryEquipmentAndSupplies
641000
CY2019Q4 nk Accrued Laboratory Equipment And Supplies
AccruedLaboratoryEquipmentAndSupplies
640000
CY2020Q4 nk Accrued Preclinical And Clinical Trial Costs
AccruedPreclinicalAndClinicalTrialCosts
638000
CY2019Q4 nk Accrued Preclinical And Clinical Trial Costs
AccruedPreclinicalAndClinicalTrialCosts
281000
CY2020Q4 nk Accrued Capital Expenditures
AccruedCapitalExpenditures
337000
CY2019Q4 nk Accrued Capital Expenditures
AccruedCapitalExpenditures
0
CY2020Q4 nk Accrued Franchise Sales Use And Property Taxes
AccruedFranchiseSalesUseAndPropertyTaxes
103000
CY2019Q4 nk Accrued Franchise Sales Use And Property Taxes
AccruedFranchiseSalesUseAndPropertyTaxes
200000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8343000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5343000
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1438000
CY2019Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
775000
CY2020Q4 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
17000
CY2019Q4 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
18000
CY2020 us-gaap Investment Income Net
InvestmentIncomeNet
366000
CY2019 us-gaap Investment Income Net
InvestmentIncomeNet
1642000
CY2018 us-gaap Investment Income Net
InvestmentIncomeNet
1857000
CY2020 us-gaap Impairment Of Investments
ImpairmentOfInvestments
0
CY2019 us-gaap Impairment Of Investments
ImpairmentOfInvestments
0
CY2018 us-gaap Impairment Of Investments
ImpairmentOfInvestments
0
CY2020Q4 us-gaap Business Acquisition Date Of Acquisition Agreement1
BusinessAcquisitionDateOfAcquisitionAgreement1
2020-12-21
CY2020Q4 us-gaap Business Acquisition Equity Interests Issued Or Issuable Number Of Shares Issued
BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
0.8190
CY2020Q4 nk Merger Exchange Ratio
MergerExchangeRatio
0.008190
CY2017Q1 us-gaap Equity Securities Without Readily Determinable Fair Value Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
8500000
CY2020Q4 us-gaap Equity Securities Without Readily Determinable Fair Value Downward Price Adjustment Cumulative Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount
1400000
CY2020Q4 us-gaap Equity Securities Without Readily Determinable Fair Value Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
7800000
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
54789000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
2000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
54772000
CY2019Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
37642000
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
10000
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
11000
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
37641000
CY2020Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
42762000
CY2020Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
19000
CY2020Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
0
CY2020Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
0
CY2019Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
11021000
CY2019Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
3000
CY2019Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
4245000
CY2019Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
8000
CY2020 us-gaap Available For Sale Securities Gross Realized Gains
AvailableForSaleSecuritiesGrossRealizedGains
4000
CY2020 us-gaap Available For Sale Securities Gross Realized Losses
AvailableForSaleSecuritiesGrossRealizedLosses
13000
CY2020 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
-9000
CY2019 us-gaap Available For Sale Securities Gross Realized Gains
AvailableForSaleSecuritiesGrossRealizedGains
4000
CY2019 us-gaap Available For Sale Securities Gross Realized Losses
AvailableForSaleSecuritiesGrossRealizedLosses
8000
CY2019 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
-4000
CY2018 us-gaap Available For Sale Securities Gross Realized Gains
AvailableForSaleSecuritiesGrossRealizedGains
3000
CY2018 us-gaap Available For Sale Securities Gross Realized Losses
AvailableForSaleSecuritiesGrossRealizedLosses
0
CY2018 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
3000
CY2019 us-gaap Litigation Settlement Amount Awarded To Other Party
LitigationSettlementAmountAwardedToOtherParty
12000000.0
CY2019Q3 us-gaap Legal Fees
LegalFees
500000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
13463000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
11729000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5500000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3206000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
9814000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10885000
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
15314000
CY2019Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
14091000
CY2020 us-gaap Operating Lease Cost
OperatingLeaseCost
4655000
CY2019 us-gaap Operating Lease Cost
OperatingLeaseCost
3898000
CY2020 us-gaap Variable Lease Cost
VariableLeaseCost
1566000
CY2019 us-gaap Variable Lease Cost
VariableLeaseCost
1215000
CY2020 us-gaap Lease Cost
LeaseCost
6221000
CY2019 us-gaap Lease Cost
LeaseCost
5113000
CY2018 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
2800000
CY2020 us-gaap Operating Lease Payments
OperatingLeasePayments
5345000
CY2019 us-gaap Operating Lease Payments
OperatingLeasePayments
4371000
CY2020Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y2M12D
CY2019Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y6M
CY2020Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.09
CY2019Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.09
CY2020 nk Operating Lease Payments Related To Options To Extend Lease Terms
OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms
3900000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
6563000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
5607000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2545000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1083000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
1115000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
614000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
17527000
CY2020Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
2213000
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
15314000
CY2020Q4 us-gaap Unrecorded Unconditional Purchase Obligation Balance Sheet Amount
UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount
2700000
CY2020Q4 us-gaap Unrecorded Unconditional Purchase Obligation Balance On First Anniversary
UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary
1200000
CY2020Q4 us-gaap Unrecorded Unconditional Purchase Obligation Balance On Second Anniversary
UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary
1200000
CY2020Q4 us-gaap Unrecorded Unconditional Purchase Obligation Balance On Third Anniversary
UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary
300000
CY2015Q4 us-gaap Stock Repurchase Program Authorized Amount1
StockRepurchaseProgramAuthorizedAmount1
50000000.0
us-gaap Stock Repurchased And Retired During Period Shares
StockRepurchasedAndRetiredDuringPeriodShares
6403489
nk Stock Repurchased And Retired Excluding Commission During Period Value
StockRepurchasedAndRetiredExcludingCommissionDuringPeriodValue
31700000
us-gaap Sales Commissions And Fees
SalesCommissionsAndFees
100000
CY2020 us-gaap Stock Repurchased And Retired During Period Shares
StockRepurchasedAndRetiredDuringPeriodShares
0
CY2019 us-gaap Stock Repurchased And Retired During Period Shares
StockRepurchasedAndRetiredDuringPeriodShares
473586
CY2019 nk Stock Repurchased And Retired Excluding Commission During Period Value
StockRepurchasedAndRetiredExcludingCommissionDuringPeriodValue
500000
CY2018 us-gaap Stock Repurchased And Retired During Period Shares
StockRepurchasedAndRetiredDuringPeriodShares
138349
CY2018 nk Stock Repurchased And Retired Excluding Commission During Period Value
StockRepurchasedAndRetiredExcludingCommissionDuringPeriodValue
200000
CY2020Q4 us-gaap Stock Repurchase Program Remaining Authorized Repurchase Amount1
StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
18300000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
108726551
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
108726551
CY2020Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
3984852
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2139000
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2627000
CY2018 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
23382000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2139000
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2627000
CY2018 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
23382000
CY2018 nk Class Of Warrant Or Rights Issued
ClassOfWarrantOrRightsIssued
0
CY2020Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
0
CY2019Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
0
CY2019 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
35200000
CY2018 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
100000
CY2020 nk Class Of Warrant Or Rights Issued
ClassOfWarrantOrRightsIssued
0
CY2019 nk Class Of Warrant Or Rights Issued
ClassOfWarrantOrRightsIssued
0
CY2018Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
0
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-92412000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-65286000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-94423000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
34000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-600000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-2306000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-92378000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-65886000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-96729000
CY2020 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0
CY2019 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0
CY2018 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0
CY2020 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
5000
CY2019 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
3000
CY2018 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
3000
CY2020 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
0
CY2019 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
0
CY2018 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
0
CY2020 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
5000
CY2019 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
3000
CY2018 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
3000
CY2020 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0
CY2019 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-79000
CY2018 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0
CY2020 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
0
CY2019 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-21000
CY2018 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-8000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
105537000
CY2020 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
0
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
78377000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
7699000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
8536000
CY2020Q4 nk Deferred Tax Assets Operating Lease Liabilities
DeferredTaxAssetsOperatingLeaseLiabilities
4254000
CY2019Q4 nk Deferred Tax Assets Operating Lease Liabilities
DeferredTaxAssetsOperatingLeaseLiabilities
3884000
CY2020Q4 nk Deferred Tax Assets Deferred Depreciation And Amortization
DeferredTaxAssetsDeferredDepreciationAndAmortization
4128000
CY2019 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
0
CY2018 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
-498000
CY2020 nk Deferred Income Tax Expense Benefit Net
DeferredIncomeTaxExpenseBenefitNet
0
CY2019 nk Deferred Income Tax Expense Benefit Net
DeferredIncomeTaxExpenseBenefitNet
-100000
CY2018 nk Deferred Income Tax Expense Benefit Net
DeferredIncomeTaxExpenseBenefitNet
-506000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
5000
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-97000
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-503000
CY2019Q4 nk Deferred Tax Assets Deferred Depreciation And Amortization
DeferredTaxAssetsDeferredDepreciationAndAmortization
2042000
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
898000
CY2019Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
898000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
762000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
775000
CY2020Q4 nk Deferred Tax Assets Leases And Other Accrued Liabilities
DeferredTaxAssetsLeasesAndOtherAccruedLiabilities
451000
CY2019Q4 nk Deferred Tax Assets Leases And Other Accrued Liabilities
DeferredTaxAssetsLeasesAndOtherAccruedLiabilities
453000
CY2020Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1419000
CY2019Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
0
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
125148000
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
94965000
CY2020Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
3739000
CY2019Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
3233000
CY2020Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
3739000
CY2019Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
3233000
CY2020Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
121409000
CY2019Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
91732000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
121409000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
91732000
CY2020Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
0
CY2019Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
0
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.077
CY2019 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.194
CY2018 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.062
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Settlements
EffectiveIncomeTaxRateReconciliationTaxSettlements
-0.001
CY2019 us-gaap Effective Income Tax Rate Reconciliation Tax Settlements
EffectiveIncomeTaxRateReconciliationTaxSettlements
0.001
CY2018 us-gaap Effective Income Tax Rate Reconciliation Tax Settlements
EffectiveIncomeTaxRateReconciliationTaxSettlements
-0.003
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
0.001
CY2019 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
0.002
CY2018 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
0.001
CY2020 nk Effective Income Tax Rate Reconciliation Stock Based Compensation Contribution
EffectiveIncomeTaxRateReconciliationStockBasedCompensationContribution
0.032
CY2019 nk Effective Income Tax Rate Reconciliation Stock Based Compensation Contribution
EffectiveIncomeTaxRateReconciliationStockBasedCompensationContribution
-0.825
CY2018 nk Effective Income Tax Rate Reconciliation Stock Based Compensation Contribution
EffectiveIncomeTaxRateReconciliationStockBasedCompensationContribution
-0.001
CY2019 us-gaap Effective Income Tax Rate Reconciliation Deductions Other
EffectiveIncomeTaxRateReconciliationDeductionsOther
-0.001
CY2018 us-gaap Effective Income Tax Rate Reconciliation Deductions Other
EffectiveIncomeTaxRateReconciliationDeductionsOther
0.003
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.321
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.805
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.267
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2019 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.002
CY2018 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.005
CY2020 nk Research And Development Cumulative Change In Ownership Percentage
ResearchAndDevelopmentCumulativeChangeInOwnershipPercentage
0.50
CY2020Q4 nk Derecognized Deferred Tax Assets
DerecognizedDeferredTaxAssets
800000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
121400000
CY2020 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
29700000
CY2019Q3 us-gaap Operating Expenses
OperatingExpenses
16077000
CY2020 us-gaap Income Tax Effects Allocated Directly To Equity Equity Transactions
IncomeTaxEffectsAllocatedDirectlyToEquityEquityTransactions
200000
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
108246579
CY2020Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
108607715
CY2019Q1 us-gaap Revenues
Revenues
5000
CY2019Q2 us-gaap Revenues
Revenues
17000
CY2019Q3 us-gaap Revenues
Revenues
12000
CY2019Q4 us-gaap Revenues
Revenues
9000
CY2019Q1 us-gaap Operating Expenses
OperatingExpenses
18340000
CY2019Q2 us-gaap Operating Expenses
OperatingExpenses
17313000
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
11983000
CY2019 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
7000
CY2019 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
3680000
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
15656000
CY2020 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
6000
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
4763000
CY2020Q4 nk Unrecognized Tax Benefits That Would Not Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate
18300000
CY2020Q1 us-gaap Revenues
Revenues
21000
CY2020Q2 us-gaap Revenues
Revenues
1000
CY2020Q3 us-gaap Revenues
Revenues
68000
CY2020Q4 us-gaap Revenues
Revenues
21000
CY2020Q1 us-gaap Operating Expenses
OperatingExpenses
18607000
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
20228000
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
21995000
CY2020Q4 us-gaap Operating Expenses
OperatingExpenses
30907000
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-18586000
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-20227000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-21927000
CY2020Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-30886000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-18383000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-20092000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-21776000
CY2020Q4 us-gaap Net Income Loss
NetIncomeLoss
-32132000
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.19
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.20
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.20
CY2020Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.30
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
98472641
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
98769687
CY2019Q4 us-gaap Operating Expenses
OperatingExpenses
16120000
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-18335000
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-17296000
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-16065000
CY2019Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-16111000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-17885000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-16682000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-15581000
CY2019Q4 us-gaap Net Income Loss
NetIncomeLoss
-15641000
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.22
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.17
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.16
CY2019Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.16
CY2019Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
81261302
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
98594355
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
98331695
CY2019Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
98419166

Files In Submission

Name View Source Status
0001564590-21-010945-index-headers.html Edgar Link pending
0001564590-21-010945-index.html Edgar Link pending
0001564590-21-010945.txt Edgar Link pending
0001564590-21-010945-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gtl21rgcbjm5000001.jpg Edgar Link pending
gtl21rgcbjm5000002.jpg Edgar Link pending
gtl21rgcbjm5000003.jpg Edgar Link pending
gtl21rgcbjm5000004.jpg Edgar Link pending
gtl21rgcbjm5000005.jpg Edgar Link pending
gtl21rgcbjm5000006.jpg Edgar Link pending
gtl21rgcbjm5000007.jpg Edgar Link pending
gtl21rgcbjm5000008.jpg Edgar Link pending
gtl21rgcbjm5000009.jpg Edgar Link pending
gtl21rgcbjm5000010.jpg Edgar Link pending
gtl21rgcbjm5000011.jpg Edgar Link pending
gtl21rgcbjm5000012.jpg Edgar Link pending
gtl21rgcbjm5000013.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
nk-10k_20201231.htm Edgar Link pending
nk-10k_20201231_htm.xml Edgar Link completed
nk-20201231.xsd Edgar Link pending
nk-20201231_cal.xml Edgar Link unprocessable
nk-20201231_def.xml Edgar Link unprocessable
nk-20201231_lab.xml Edgar Link unprocessable
nk-20201231_pre.xml Edgar Link unprocessable
nk-ex1035_433.htm Edgar Link pending
nk-ex211_10.htm Edgar Link pending
nk-ex231_7.htm Edgar Link pending
nk-ex311_8.htm Edgar Link pending
nk-ex312_6.htm Edgar Link pending
nk-ex321_9.htm Edgar Link pending
nk-ex322_11.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending